stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Book value per share
Celldex Therapeutics, Inc.'s book value per share at the end of fiscal 2025 was 7.9×, down 31.6% from 11.6× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 9.2×. Over the past ten years it has ranged from 6.5× (fiscal 2019) to 44.8× (fiscal 2015); the current reading is higher than 36% of that period. Celldex Therapeutics, Inc. ranks 81st of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 7.9× | (31.58%) |
| FY2024 | 11.6× | 30.96% |
| FY2023 | 8.9× | 27.33% |
| FY2022 | 7.0× | (28.90%) |
| FY2021 | 9.8× | 38.53% |
| FY2020 | 7.1× | 8.98% |
| FY2019 | 6.5× | (45.45%) |
| FY2018 | 11.9× | (56.92%) |
| FY2017 | 27.6× | (29.66%) |
| FY2016 | 39.2× | (12.50%) |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 9.2× | 33.94% |
| Mar 2026 | 6.9× | (13.64%) |
| Dec 2025 | 7.9× | (11.90%) |
| Sep 2025 | 9.0× | (8.74%) |
| 42 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. | 9.2× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| PHVS Pharvaris N.V. compare | 5.1× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. compare | 4.6× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement